Developing Resilience in Transgender and Nonbinary Individuals - Exploring the Impact of Social Challenges in the Metaverse
Launched by UNIVERSITY OF BUCHAREST · May 4, 2025
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to see how effective a virtual support group in the Metaverse can be for transgender and nonbinary individuals. The main goal is to help these individuals build resilience, which means the ability to cope with challenges and bounce back from difficulties. The trial will compare the experiences of those participating in the support group to a control group and a waitlist group to see if the virtual setting helps improve their self-compassion and overall well-being.
To participate, individuals should identify as gender diverse and have a stable understanding of their gender identity, or they may be questioning it. However, people who have a formal diagnosis of a mental disorder or are under 18 years old will not be eligible. While the trial is not yet recruiting, those who join can expect to engage in discussions and activities aimed at enhancing their resilience in a supportive online community.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Gender diverse people with a stable gender-identity or questioning
- Exclusion Criteria:
- • Formally diagnosed with a mental disorder
- • Not being part of the gender minority population
- • Younger than 18
About University Of Bucharest
The University of Bucharest, a prestigious institution of higher education and research in Romania, serves as a prominent clinical trial sponsor dedicated to advancing scientific knowledge and improving public health outcomes. With a robust framework for research and innovation, the university fosters interdisciplinary collaboration among leading experts in various fields, including medicine, pharmacology, and social sciences. Through its commitment to ethical research practices and rigorous scientific standards, the University of Bucharest aims to contribute valuable insights and evidence-based solutions to contemporary healthcare challenges, while ensuring the safety and well-being of trial participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bucharest, , Romania
Patients applied
Trial Officials
Cezar Giosan, PhD
Principal Investigator
University of Bucharest
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported